Regeneron CEO Len Schleifer used the stage during the first day at the 44th annual J.P. Morgan Healthcare Conference to underscore the company’s scientific-driven strategy, placing an emphasis on its broad pipeline which spans six major therapeutic areas along with a commitment to near-term data readouts which are expected to drive continued growth.

During his presentation, Schleifer framed 2026 as a pivotal year, with multiple regulatory filings, clinical milestones, and new product launches on the horizon. He also described Regeneron as a “unique” biopharmaceutical company built on proprietary platforms such as the VelocImmune technology, the Regeneron Genetics Center, and high-throughput proteomics and genomics capabilities. These tools, he noted, enable rapid discovery of therapeutic candidates and underpin the company’s ability to bring innovative medicines to patients efficiently.

Schleifer emphasized that the company’s platform-driven approach allowed Regeneron to deliver 14 internally discovered approvals over the past 15 years, averaging roughly one major approval annually.

Regeneron’s presentation highlighted the company’s 2025 commercial performance, particularly within its retina and immunology franchises. According to Schleifer, fourth-quarter 2025 net sales, including Eylea HD and Ilia HD, reached upwards of $1.1 billion in the U.S., with Eylea HD showing growth of 66% year-over-year.

Schleifer pointed to label expansions and dosing enhancements, as well as FDA’s looming decision on a prefilled syringe as the key components of continued growth for the company.

Looking ahead, Schleifer and Regeneron CSO George Yancopoulos outlined five late-stage programs poised to generate meaningful near-term data across multiple therapeutic areas, including oncology, obesity, complement-mediated diseases, anticoagulation, and immunology.

Key initiatives include:

• Checkpoint inhibitors: Moderna is looking to building on collected proof-of-concept data with a pivotal trial of the LAG-3 antibody combination with Libtayo in metastatic melanoma.
• Multiple myeloma: Conducting advanced studies of BCMA-targeted therapies exploring monotherapy and simplified combination regimens in early-line settings, aiming for high complete response rates and potential prevention of disease progression.
• Complement inhibition: Comprised of novel antibody and siRNA-based approaches targeting C5, with early data in paroxysmal nocturnal hemoglobinuria demonstrating superior LDH control versus current standards and expansion into generalized myasthenia gravis and geographic atrophy programs.
• Factor XI antibodies: Includes next-generation anticoagulants designed to optimize efficacy while minimizing bleeding risk, with multiple phase III trials planned for 2026, addressing stroke prevention, post-surgical DVT, and atrial fibrillation.
• Obesity: The company is looking to fast-track programs combining its in-licensed GLP-1 therapy with proprietary antibodies to address comorbid conditions to enable a holistic therapeutic approach.

Schleifer emphasized Regeneron’s continued focus on internal R&D investment, mentioning the company is allocating an estimated $6 billion in 2026 which will be supplemented by $7 billion in U.S. capital expenditures to support manufacturing and research capabilities.

Schleifer closed by underscoring Regeneron’s mission-driven focus: combining scientific rigor with patient-centered innovation. He highlighted gene therapy and antibody programs targeting children with serious conditions as reminders of the company’s commitment to addressing both high-commercial-impact opportunities and areas of greatest unmet need.

Sources

1. Regeneron Pharmaceutical Inc. J.P. Morgan Healthcare Conference Regeneron Pharmaceuticals January 12, 2026 https://jpmorgan.metameetings.net/events/healthcare26/sessions/317182-regeneron-pharmaceuticals-inc/webcast?gpu_only=true&kiosk=true